Apix GlycoBiomarker array kit provides a new method of multiplex profiling of glycans on serum glycoproteins and is based on technology licensed exclusively from the Van Andel Research Institute
"Glycan structures are increasingly being investigated for their role in various cancers".
"This new approach provides a powerful means of profiling the patterns of these structures across various disease states", said Brian Haab of the Van Andel Research Institute, inventor of the technology.
"Gentel is proud to work with thought leaders like Haab and incorporate his innovations into powerful analytical tools that will benefit oncology researchers around the world", said Randall Durnell, Gentel's vice president of commercial operations.
The kit contains an antibody microarray that is engineered to capture specific glycoproteins of interest from serum samples and to detect glycan patterns using biotinylated lectins.
A critical feature of the kit is the chemical derivitisation of the immobilised capture antibodies (>40 total proteins) that prevents non-specific binding of the lectins to glycans.
Research applications include characterization of disease-associated glycan alterations, biomarker discovery, and analysis of factors that regulate glycan structures.
The kit also expands Gentel's offering of content-based protein microarrays designed to meet the demands of the rapidly growing field of multiplex proteomics research.
